| Systematic (IUPAC) name | |
|---|---|
| (1-methyl-4-phenyl-3-prop-2-enylpiperidin-4-yl) propanoate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? (UK) Schedule I (US) |
| Identifiers | |
| CAS number | 25384-17-2 |
| ATC code | None |
| PubChem | CID 32938 |
| DrugBank | DB01542 |
| ChemSpider | 30495 |
| UNII | 4343OEZ18O |
| Synonyms | Allylprodine |
| Chemical data | |
| Formula | C18H25NO2 |
| Mol. mass | 287.397 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Allylprodine[1] is an opioid analgesic that is an analogue of prodine. It was discovered in by Hoffman-La Roche in 1957 during research into the related drug pethidine. Derivatives were tested to prove the theory that phenolic & non-phenolic opioids bind at different sites of the opiate receptor.
Allylprodine is more potent as an analgesic (23 times morphine) than other similar drugs such as α-prodine, due to the allyl group binding to an additional amino acid target in the binding site on the μ-opioid receptor. It is also stereoselective, with one isomer being much more active.[2][3]
Allylprodine produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting and respiratory depression which may be harmful or fatal.
| This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)